Search clinical trials for: [14C]-LOXO-305

Total 6039 results

Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants

Healthy

United States
Hoffmann-La Roche

Completed

Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Lymphoma, Non-Hodgkin | B-cell Lymphoma | Multiple Myeloma | Lymphoma, Mantle-Cell | Waldenstrom Macroglobulinemia | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, B-cell Marginal Zone

United States, France, Poland, Italy
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants

Healthy

United States
Taiho Pharmaceutical Co., Ltd.

Completed

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

Healthy Male Subjects

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

Mass Balance Study of [14C] TAS-205 in Healthy Volunteers

Healthy Male Subjects

Japan
Vivozon, Inc.

Completed

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

Healthy Adult Male

United States
Rachel Lieberman

Terminated

Capsular Tension Rings in Intraocular Lens Rotation

Cataract | Ophthalmoplegia | Ophthalmologic Complication

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants

Healthy

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants

Healthy

United States
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib

Healthy

China
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Lymphoma, B-Cell, Marginal Zone | Leukemia, Lymphoid | Leukemia, Lymphocytic, Chronic, B-Cell

China
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants

Healthy | Renal Insufficiency

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants

Healthy

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

Hepatic Insufficiency | Healthy

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Not yet recruiting

A Study of [14C]-LOXO-783 in Healthy Adult Participants

Healthy

United States
Loxo Oncology, Inc.

Completed

Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants

Healthy Volunteers

United States
Taisho Pharmaceutical Co., Ltd.

Completed

Mass Balance Study of TS-142 in Healthy Adult Subjects.

Healthy Male Subjects

Japan
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Hoffmann-La Roche

Completed

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Solid Tumors

Hungary
Merck KGaA, Darmstadt, Germany
Threshold Pharmaceuticals

Completed

A Phase 1 TH-302 Mass Balance Trial

Solid Tumor

Germany
Loxo Oncology, Inc.

Available

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Lymphoma, Mantle-Cell | Waldenstrom Macroglobulinemia | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, Lymphocytic, Small | Ritcher's Transformation, Syndrome
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Takeda

Completed

TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study

Healthy Volunteers

United Kingdom
Medical College of Wisconsin

Not yet recruiting

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Central Nervous System Neoplasm | Solid Neoplasm | Recurrent Acute Leukemia | Refractory Acute Leukemia | Infantile Fibrosarcoma

United States, Canada
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)

Chronic Lymphocytic Leukemia | Leukemia, B-cell | Small Lymphocytic Lymphoma | Leukemia, Lymphocytic

United States, Spain, Canada, Korea, Republic of, Taiwan, Australia, Japan, New Zealand, Italy, Czechia, China, Hungary, Israel, Belgium, France, Poland, Germany, Argentina, United Kingdom, Brazil, Turkey, Chile, Austria
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

Healthy

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Carcinoma, Non-Small-Cell Lung | Thyroid Neoplasms

United States
Eli Lilly and Company
Loxo Oncology, Inc.

No longer available

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Carcinoma, Non-Small-Cell Lung | Thyroid Neoplasms
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants

Healthy

United States
M.D. Anderson Cancer Center
Loxo Oncology

Recruiting

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Hematologic Malignancy

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

Healthy | Renal Insufficiency

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Completed

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

Healthy

United States
Orion Corporation, Orion Pharma
Bayer

Completed

Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects (ARIADME)

Healthy

United Kingdom
Loxo Oncology, Inc.
Eli Lilly and Company

Available

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Breast Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Papillary Thyroid Cancer | Other Solid Tumors With Evidence of Activating RET Alteration

Spain, United States, Australia, France, Germany, Israel, Italy, Japan, New Zealand, Poland, Singapore, Switzerland
Loxo Oncology, Inc.
Eli Lilly and Company

Completed

A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants

Healthy

Singapore
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-321)

Solid Tumor | Medullary Thyroid Cancer

China
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Healthy | Hepatic Impairment

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Completed

A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

Healthy

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Selpercatinib (LY3527723) in Healthy Participants

Healthy

United States
M.D. Anderson Cancer Center

Recruiting

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

Carcinoma, Non-Small-Cell Lung

United States, Denmark, Taiwan, China, Canada, Spain, Germany, Japan, United Kingdom, Brazil, India, Korea, Republic of, Australia, Italy, Norway, Israel, Greece, Turkey, Netherlands, Austria, Belgium, Hong Kong, Poland, Puerto Rico, Cz... and more
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Medullary Thyroid Cancer

United States, Canada, Spain, China, Taiwan, Australia, Japan, India, Belgium, Germany, France, Netherlands, Czechia, Brazil, Korea, Republic of, United Kingdom, Italy, Israel, Greece, Poland, Russian Federation
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance (Mode of Administration) of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar | Senile Lentigo

Georgia
Laekna Limited

Completed

Human Mass Balance and Biotransformation Study of [14C]Afuresertib

Healthy Volunteer

China
Indivior Inc.

Completed

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

Opioid Use Disorder

United States
Arcus Biosciences, Inc.
Gilead Sciences

Completed

A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer

Healthy Participants

Netherlands
Biogen
Denali Therapeutics Inc.

Completed

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

Healthy Volunteers

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Human AME Study for Omaveloxolone

Healthy Male Subjects

United States

Search clinical trials for: [14C]-LOXO-305

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations